Oryn Therapeutics


Oryn Therapeutics is pioneering a new frontier in drug development by emulating nature’s defense mechanisms and introducing a novel class of proprietary macrocyclic peptides designed to restore immune balance in complex and devastating diseases. The company aims to improve quality of life by creating safer, more efficacious treatments for autoimmune, chronic inflammatory diseases, drug-resistant infections, and cancer, utilizing a paradigm-changing approach based on evolutionary biology.

Industries

biotechnology
health-care

Nr. of Employees

small (1-50)

Oryn Therapeutics

Vacaville, California, United States, North America


Products

Macrocyclic peptide therapeutic candidates (bioinspired theta-defensin analogs)

A class of bioinspired macrocyclic peptides designed to be stable, low in toxicity and immunogenicity, and synthetically accessible for treatment of autoimmune, inflammatory, infectious diseases and cancer.


Services

Early-phase clinical development

Design and conduct of Phase I clinical studies focused on safety, tolerability and PK for peptide therapeutics.

Preclinical and CMC development for peptide candidates

Preclinical efficacy and safety studies combined with chemistry, manufacturing and controls (CMC) activities to prepare peptide candidates for clinical testing.

Expertise Areas

  • Macrocyclic peptide therapeutics
  • Immunomodulation
  • Autoimmune and chronic inflammatory disease therapeutics
  • Infectious disease therapeutics
  • Show More (4)

Key Technologies

  • Macrocyclic peptide engineering
  • Structure-guided peptide design
  • Synthetic peptide manufacturing and scale-up
  • Immunogenicity and toxicity assays
  • Show More (3)

Similar organizations

Browse all ORGANIZATIONS

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.